Generex Biotechnology Corporation (PINK: GNBT) announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The AE37 vaccine is being developed by its wholly-owned subsidiary, Antigen Express, Inc.
AE37 is the subject of an ongoing, controlled, randomized, and single-blinded Phase 2 clinical study in human epidermal growth factor receptor 2 (HER2) expressing patients with either node positive or high-risk node-negative breast cancer. Patients are randomized to receive AE37 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) or GM-CSF alone (control). The primary endpoint is a reduction in cancer relapse after two years.
Generex Biotechnology Corporation is a development-stage company. The Company is engaged in the research, development and commercialization of drug delivery systems and technologies. The Company focuses at the technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator.
Shares of the company closed at $0.334 in Wednesday’s trading session.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial adviser.